Skip to content
Shorla Oncology: A Leader in Innovative Oncology Solutions
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Company Updates

Banner

Shorla Oncology attending Jefferies Healthcare Conference

October 31st 2023

Read More

Logo

PRESS RELEASE: Shorla Oncology Announces US Acquisition of Jylamvo, an Oncology and Autoimmune Drug from Therakind

October 31st 2023

Read More

Logo

Shorla Oncology at BIO-Europe 2023

October 20th 2023

Read More

Logo

Shorla Oncology at CPhI Barcelona 2023

October 10th 2023

Read More

Banner

PRESS RELEASE: Shorla Oncology Secures $35M Series B Funding Round to Advance its Oncology Product Portfolio

October 4th 2023

Read More

Logo

Shorla Oncology at LSX USA Congress

September 1st 2023

Read More

Logo

Shorla Oncology Announces Licensing Agreement and Strategic Partnership for Rights to Market Chemotherapy Drug, PIP-101, in the United States

July 14th 2023

Read More

Logo

100k in 30 days for breast cancer

July 4th 2023

Read More

Orlaith Mid West Event

Mid-West Building Better Business event

May 31st 2023

Read More

Older posts
Newer posts
Page1 … Page4 Page5 Page6 … Page12
Logo

IRELAND HQ:
Questum Acceleration Center,
Ballingarrane Science & Technology Park,
Clonmel, Co. Tipperary,
E91 V329, Ireland

Shorla Pharma Ltd trading as Shorla Oncology®

All trademarks are the property of their respective owners.

US OFFICE:
245 Main St.,
2nd floor,
Cambridge,
MA 02142, USA

SITEMAP

PRIVACY POLICY

CALIFORNIA COMPLIANCE PROGRAM DECLARATION

Company number: 618033
©SHORLA ONCOLOGY® 2025

© 2025 Shorla Oncology: A Leader in Innovative Oncology Solutions • Built with GeneratePress
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Now approved for use in Pediatrics

  • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA).
  • Treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.

Please click here for the full Prescribing information, including Boxed Warning regarding embryo-fetal toxicity, hypersensitivity reactions, and severe adverse reactions.